恩扎鲁胺
医学
前列腺癌
雄激素受体
危险系数
内科学
肿瘤科
单变量分析
多元分析
多西紫杉醇
睾酮(贴片)
比例危险模型
泌尿科
癌症
置信区间
作者
Shinichi Sakamoto,Koji Ando,Sangjon Pae,Xue Zhao,Kazuko Sakai,Kodai Sato,Shingo Saito,Yasutaka Yamada,Junryo Rii,Yusuke Goto,Tomokazu Sazuka,Yusuke Imamura,Naohiko Anzai,Koichiro Akakura,Kazuto Nishio,Tomohiko Ichikawa
标识
DOI:10.21873/anticanres.16853
摘要
Background/Aim: The prognostic significance of androgen receptor amplification (AR amp) in cell-free DNA (cfDNA) was studied in Japanese patients with castration-resistant prostate cancer (CRPC). Patients and Methods: A total of 120 serum samples were obtained from 38 patients with CRPC. Serum cfDNA was purified and the AR copy number was determined. Factors associated with progression-free survival (PFS) and overall survival (OS) were statistically investigated. Results: The number of patients administered enzalutamide (Enza)/abiraterone (Abi)/docetaxel (DTX) was 33/25/11, respectively. The median PSA was 16.5 ng/ml. Thirty patients (79%) had bone metastases and three patients (7.9%) had lung metastases. The median follow-up was 655 days. The median initial AR copy number was 1.27 (1.10-11.50); an AR copy number of 1.27 or higher was defined as an AR-amp. Regarding PFS, the presence of AR-amp, Gleason score (GS), and ALP were significant factors in univariate analysis. In multivariate analysis, AR amplification was an independent prognostic factor (hazard ratio=7.7, p=0.0035). For OS, PSA and AR-amp were significant factors. In multivariate analysis, AR-amp (hazard ratio=4.65, p=0.0188) was the only independent prognostic factor. Conclusion: AR-amp was associated with high nadir PSA and low iPSA/PSA ratio. AR-amp was significantly associated with poor prognosis in Japanese patients with CRPC.
科研通智能强力驱动
Strongly Powered by AbleSci AI